Stockscreener 앱 받기
0.701
4.02%
-0.0293
시간 외 거래:
.72
0.019
+2.71%
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics shareholders approve reverse stock split and key proposals By Investing.com - Investing.com South Africa
Dermata Therapeutics Holds Annual Stockholders Meeting - TipRanks
What makes Dermata Therapeutics Inc. stock price move sharplyPro Trader Stock Focus - Newser
How Dermata Therapeutics Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
What makes Dermata Therapeutics Inc. Equity Warrant stock price move sharplyFree Low-Risk Investment Plans - Newser
Why Dermata Therapeutics Inc. stock attracts strong analyst attentionExpert Backed Predictions - Newser
How Dermata Therapeutics Inc. Equity Warrant stock performs during market volatilitySecure Growth Trading Plan - Newser
Why Dermata Therapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
Dermata Therapeutics (DRMA) Stock Price, News & Analysis - MarketBeat
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire
Breakthrough: First-Ever Topical Botulinum Toxin for Hyperhidrosis Receives Australian Patent - Stock Titan
Dermata Therapeutics (NASDAQ:DRMA) Trading Up 4.7% – What’s Next? - Defense World
Dermata Therapeutics receives extension from Nasdaq panel to meet minimum bid price - Investing.com
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split - TipRanks
Primary Axillary Hyperhidrosis Pipeline 2025: Groundbreaking - openPR.com
Dermata stock hits 52-week low at $0.69 amid market challenges - Investing.com India
Dermata stock hits 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Down 57.0% in May - Defense World
Dermata Therapeutics (NASDAQ:DRMA) Stock Price Down 2% – Time to Sell? - Defense World
Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $3.00 - Defense World
Dermata gears up for phase 3 trial of XYNGARI By Investing.com - Investing.com Nigeria
Maxim Group cuts Dermata Therapeutics target to $3 By Investing.com - Investing.com Nigeria
Dermata gears up for phase 3 trial of XYNGARI - Investing.com
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial - TipRanks
Dermata Therapeutics IncPotential NDA Filing For Xyngari In H1 2028SEC Filing - marketscreener.com
Maxim Group cuts Dermata Therapeutics target to $3 - Investing.com
Dermata Therapeutics (DRMA) Price Target Cut Amid Capital Raise - GuruFocus
Dermata Faces Nasdaq Delisting Risk Over Bid Price - TipRanks
Dermata (DRMA) Achieves Positive Phase 3 Trial Results for Acne Treatment | DRMA Stock News - GuruFocus
DRMA: Substantial Cash Increase Enhances Financial Stability | DRMA Stock News - GuruFocus
Dermata Reports Positive Phase 3 Trial Results - TipRanks
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Revolutionary Once-Weekly Natural Acne Treatment Achieves Breakthrough in Phase 3 Trial Results - Stock Titan
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks - ACCESS Newswire
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
DRMAWDermata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Dermata Therapeutics stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
3.40%
2.49%
자본화:
|
볼륨(24시간):